Viking Therapeutics Announces Positive Top-Line Results from Phase 2 Study of VK2809 in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Elevated LDL-Cholesterol
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Viking Therapeutic (VKTX) PT Raised to $28 at SunTrust Robinson Humphrey
September 18, 2018 3:39 PM EDTSunTrust Robinson Humphrey analyst Edward Nash raised the price target on Viking Therapeutic (NASDAQ: VKTX) to $28.00 (from $14.00) while maintaining a Buy rating.
Nash commented, "Viking announced promising results from a Phase II study of VK2809 in NAFLD/hypercholesterolemia. 12-week treatment... More
Viking Therapeutic (VKTX) PT Raised to $28 at Maxim Group, Matching 'Street High'
September 18, 2018 12:31 PM EDTMaxim Group analyst Jason McCarthy raised the price target on Viking Therapeutic (NASDAQ: VKTX) to $28.00 (from $14.00) while maintaining a Buy rating. The new price target matches a Street High.
The analyst highlights:
VKTX shares are up sharply (~+80%) after announcing positive top-line 12-week P2 data for VK2809, an oral thyroid beta receptor agonist (TR), in Non-Alcoholic Fatty... MoreViking Therapeutic (VKTX) PT Raised to 'Street High' $28 at H.C. Wainwright
September 18, 2018 11:57 AM EDTH.C. Wainwright analyst Joseph Pantginis raised the price target on Viking Therapeutic (NASDAQ: VKTX) to a 'Street High' $28.00 (from $15.00) while maintaining a Buy rating.
The analsyt commented, "This morning, the highly anticipated VK2809 top-line data in non-alcoholic fatty liver disease (NAFLD) and... More
Viking Therapeutics (VKTX) Climbs 140% After Shares Resume Trading
September 18, 2018 7:37 AM EDTViking Therapeutics (NASDAQ: VKTX) Climbs 140% After Shares Resume Trading
... MoreViking Therapeutics (VKTX) to Resume Trading at 7:35 am ET
September 18, 2018 7:17 AM EDTViking Therapeutics (NASDAQ: VKTX) to Resume Trading at 7:35 am ET
... More